IGF-1 (Mecasermin)

Insulin-Like Growth Factor 1 / Mecasermin (Increlex)

Evidence & Status

  • FDA Approved
  • Strong Human Evidence
  • Established

At a Glance

Mecasermin is a distinct recombinant prescription product with a narrow labeled pediatric indication; it is not interchangeable with IGF-1 research analogs or consumer uses.

Plain English

This entry is about a specific prescription form of IGF-1 used under specialist care for a rare pediatric condition. It does not establish a treatment for aging, muscle gain, athletic performance, or general wellness.

Overview

IGF-1 is an endogenous peptide hormone; mecasermin is recombinant human IGF-1 supplied as INCRELEX. This record concerns the labeled mecasermin product and must not transfer claims to endogenous IGF-1, IGF-1 LR3, performance-enhancement use, or aging interventions. INCRELEX is indicated for children with severe primary IGF-1 deficiency and is not indicated for secondary forms of IGF-1 deficiency.

Research Summary

The cited source is the current INCRELEX prescribing information for its narrow pediatric indication, contraindications, administration requirements, and risks. It is not evidence of benefit for aging, athletic performance, body composition, ALS, or unrelated endocrine conditions.

Research Areas

  • Severe primary IGF-1 deficiency
  • Pediatric endocrine care

Safety & Risks

Serious Risks

  • Severe hypoglycemia is a labeled risk; dosing is timed in relation to food and patients require monitoring.
  • INCRELEX is contraindicated in patients with malignant neoplasia and should be discontinued if evidence of malignancy develops.
  • Intracranial hypertension and slipped capital femoral epiphysis are listed warnings in the pediatric product label.
United States
INCRELEX (mecasermin) is a prescription product with a narrow FDA-labeled pediatric indication for severe primary IGF-1 deficiency; its label excludes use for secondary forms of IGF-1 deficiency.
United Kingdom
Not assessed in this record.
Australia
Not assessed in this record.
Canada
Not assessed in this record.